NCT07213765 - Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease | Biotech Hunter

Enrollment

188

Participants

Timeline

Start Date

July 24, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

December 31, 2028

Conditions

Mycobacterium Avium Complex Pulmonary Disease

Interventions

DRUG

Contezolid

contezolid 800mg po q12h\*6m

DRUG

Azithromycin

azithromycin 500mg po tiw (250mg po tiw for BW under 50kg)\*6m

DRUG

Azithromycin

azithromycin 500mg po tiw (250mg po tiw for BW under 50kg)\*12m

DRUG

Ethambutol (E)

ethambutol 25mg/kg po tiw\*6m

DRUG

Ethambutol (E)

ethambutol 25mg/kg po tiw\*12m

DRUG

Rifampicin (R)

rifampicin 600mg po tiw (450mg po tiw for BW under 50kg)\*6m

DRUG

Rifampicin (R)

rifampicin 600mg po tiw (450mg po tiw for BW under 50kg)\*12m

Trial Locations (6)

RECRUITING

Anhui Chest Hospital, Hefei

RECRUITING

Beijing Chest Hospital, Capital Medical University, Beijing

RECRUITING

China-Japan Friendship Hospital, Beijing

NOT_YET_RECRUITING

Guangzhou Chest Hospital, Guangzhou

RECRUITING

Jiangxi Chest Hospital, Nanchang

NOT_YET_RECRUITING

Shanghai Pulmonary Hospital, Shanghai